

Acta Cryst. (1996). C52, 2260–2261

Anticancer and Antifertility Agents. II. *N,N'*-Hexamethylenebis(3-pyridinecarboxamide)

Q. LIU, S.-W. ZHANG,* Y. G. WEI AND M.-C. SHAO

Department of Chemistry, Peking University, Beijing 100871, People's Republic of China. E-mail: zhangsw@pschnetware.pku.edu.cn


(Received 23 November 1995; accepted 18 April 1996)

Abstract

The centrosymmetric molecule *N,N'*-hexamethylenebis(3-pyridinecarboxamide), C₁₈H₂₂N₄O₂, contains a crystallographic centre of inversion, with only half of the molecule constituting the asymmetric unit. There are intermolecular N—H···O=C hydrogen bonds [N···O 2.996 (2) Å] present in the structure.

Comment

Hexamethylenebisacetamide (HMBA) is an agent currently undergoing clinical trials that induces differentiation of certain types of cancer cells to non-malignant phenotypes (Andreoff *et al.*, 1992). In order to discover more effective anticancer agents, identify structure–activity relationships, understand molecular mechanisms and provide structural data for drug design, a series of compounds structurally related to HMBA have been synthesized and their crystal structures determined (Zhang, Liu, Wei & Shao, 1996). The title compound, (I), is one of these compounds.



The title compound (Fig. 1) can inhibit proliferation of lung cancer cells (Ao, Tanaka, Nakao, Yamagami & Fujii, 1991) and it has been proven from pharmacological experiments (Zhang & Wang, 1980; Zhang, Xing & Wang, 1982) to possess antifertility activity in male rats. It can inhibit spermatogenesis over a long period and does not produce any toxic effects with effective dosage (Li, Qin, Zhang & Li, 1979). Because of this, it may turn out to be an improved male sterilization drug.

Because intermolecular N—H···O=C hydrogen bonds occur in HMBA (Bailey, 1955), this kind of intermolecular interaction could be assumed to occur in the title compound and is realised along the approximate direction of the *b* axis, where there are intermolecular N—




Fig. 1. View of C₁₈H₂₂N₄O₂ showing the labelling of the non-H atoms. Displacement ellipsoids are shown at 50% probability levels and H atoms are drawn as small circles of arbitrary radii.

H···O=C hydrogen bonds of length 2.996 (2) Å [O=C at *x*, *y* − 1, *z*].

Experimental

The title compound was prepared by condensation of nicotinic acid and 1,6-hexanediamine in a 2:1 molar ratio using Schlenk techniques. Recrystallization was from ethanol solution. The density *D_m* was measured by flotation in CHCl₃/Cl(CH₂)₃Cl solution.

Crystal data

C₁₈H₂₂N₄O₂
M_r = 326.4
 Monoclinic
*P*2₁/*n*
a = 5.2240 (10) Å
b = 5.0960 (10) Å
c = 31.006 (6) Å
 β = 94.53 (3)°
V = 822.8 (3) Å³
Z = 2
D_x = 1.317 Mg m^{−3}
D_m = 1.3167 (10) Mg m^{−3}

Data collection

Rigaku AFC-6S diffractometer
 2θ scans
 Absorption correction:
 ψ scans (Coppens, Leis-erowitz & Rabinovich, 1965)
T_{min} = 0.995, *T_{max}* = 1.000
 2293 measured reflections
 1892 independent reflections

Refinement

Refinement on *F*
R = 0.0411
 wR = 0.0639
S = 1.62

Mo *K*α radiation
 λ = 0.71073 Å
 Cell parameters from 25 reflections
 θ = 6–10°
 μ = 0.083 mm^{−1}
T = 296.0 (1) K
 Rod
 0.40 × 0.20 × 0.20 mm
 Colourless

1537 observed reflections
 $[F \geq 4.0\sigma(F)]$
 $R_{\text{int}} = 0.032$
 $\theta_{\text{max}} = 27.5^\circ$
 $h = 0 \rightarrow 6$
 $k = 0 \rightarrow 6$
 $l = -39 \rightarrow 40$
 3 standard reflections monitored every 150 reflections
 intensity decay: 3%

$(\Delta/\sigma)_{\text{max}} = 0.003$
 $\Delta\rho_{\text{max}} = 0.22 \text{ e } \text{Å}^{-3}$
 $\Delta\rho_{\text{min}} = -0.16 \text{ e } \text{Å}^{-3}$
 Extinction correction: none

1537 reflections
153 parameters
All H-atom parameters refined
 $w = 1/[\sigma^2(F) + 0.001F^2]$

Atomic scattering factors from *International Tables for X-ray Crystallography* (1974, Vol. IV, Table 2.3.1)

Sheldrick, G. M. (1990). *SHELXTL-Plus*. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.
Spek, A. L. (1990). *Acta Cryst.* **A46**, C-34.
Zhang, S.-W., Liu, Q., Wei, Y. G. & Shao, M.-C. (1996). *Acta Cryst.* **C52**, 1238–1239.
Zhang, J.-Z. & Wang, J. (1980). *Tien-chin I Yao*, **8**, 741–742.
Zhang, J.-Z., Xing, L.-S. & Wang, Y.-L. (1982). *Tien-chin I Yao*, **10**, 617–618.

Table 1. Fractional atomic coordinates and equivalent isotropic displacement parameters (\AA^2)

$$U_{eq} = (1/3)\sum_i \sum_j U_{ij} a_i^* a_j$$

	x	y	z	U_{eq}
O	0.3725 (2)	0.6828 (2)	0.1022 (1)	0.051 (1)
N(1)	0.4777 (2)	0.2584 (2)	0.0950 (1)	0.039 (1)
N(2)	-0.1524 (2)	0.5030 (3)	0.1916 (1)	0.053 (1)
C(1)	0.6379 (3)	0.3119 (2)	0.0595 (1)	0.040 (1)
C(2)	0.7755 (3)	0.0686 (3)	0.0460 (1)	0.039 (1)
C(3)	0.9338 (3)	0.1218 (3)	0.0077 (1)	0.038 (1)
C(4)	0.3571 (2)	0.4528 (2)	0.1139 (1)	0.036 (1)
C(5)	0.2004 (2)	0.3792 (2)	0.1505 (1)	0.036 (1)
C(6)	0.2505 (3)	0.1635 (3)	0.1768 (1)	0.043 (1)
C(7)	0.0975 (3)	0.1217 (3)	0.2108 (1)	0.050 (1)
C(8)	-0.0978 (3)	0.2956 (3)	0.2168 (1)	0.052 (1)
C(9)	-0.0035 (3)	0.5418 (3)	0.1592 (1)	0.043 (1)

Table 2. Selected geometric parameters (\AA , $^\circ$)

O—C(4)	1.232 (2)	C(3)—C(3')	1.517 (3)
N(1)—C(1)	1.460 (2)	C(4)—C(5)	1.498 (2)
N(1)—C(4)	1.334 (2)	C(5)—C(6)	1.381 (2)
N(2)—C(8)	1.331 (2)	C(5)—C(9)	1.392 (2)
N(2)—C(9)	1.334 (2)	C(6)—C(7)	1.386 (2)
C(1)—C(2)	1.509 (2)	C(7)—C(8)	1.375 (2)
C(2)—C(3)	1.523 (2)		
C(1)—N(1)—C(4)	120.7 (1)	C(4)—C(5)—C(6)	123.9 (1)
C(8)—N(2)—C(9)	116.6 (1)	C(4)—C(5)—C(9)	118.0 (1)
N(1)—C(1)—C(2)	111.7 (1)	C(6)—C(5)—C(9)	118.1 (1)
C(1)—C(2)—C(3)	111.7 (1)	C(5)—C(6)—C(7)	118.5 (1)
C(2)—C(3)—C(3')	112.9 (1)	C(6)—C(7)—C(8)	118.9 (1)
O—C(4)—N(1)	122.2 (1)	N(2)—C(8)—C(7)	124.0 (1)
O—C(4)—C(5)	120.9 (1)	N(2)—C(9)—C(5)	123.9 (1)
N(1)—C(4)—C(5)	116.9 (1)		

Symmetry code: (i) $2 - x, -y, -z$.

The structure was solved and refined using *SHELXTL-Plus* (Sheldrick, 1990). All calculations were carried out using *SHELXTL-Plus* and the figure was produced with *PLATON* (Spek, 1990).

This work was supported by the National Natural Science Foundation of China.

Lists of structure factors, anisotropic displacement parameters, H-atom coordinates, complete geometry and torsion angles have been deposited with the IUCr (Reference: TA1081). Copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England.

References

- Andreoff, M., Stone, R., Michaeli, J., Young, C. W., Tong, W. P., Sogoloff, H., Ervin, T., Kufe, D., Rifking, R. A. & Marks, P. A. (1992). *Blood*, **80**, 2604–2609.
Ao, E., Tanaka, H., Nakao, T., Yamagami, K. & Fujii, A. (1991). Japanese Patent No. 03 81,222 (5 April 1991).
Bailey, M. (1955). *Acta Cryst.* **8**, 575–578.
Coppens, P., Leiserowitz, L. & Rabinovich, D. (1965). *Acta Cryst.* **18**, 1035–1038.
Li, M.-M., Qin, Q., Zhang, J.-Z. & Li, R.-X. (1979). *Tien-chin I Yao*, **7**, 354–356.

Acta Cryst. (1996). **C52**, 2261–2263

17 α -Ethynyl-19-nor-3-oxo-4-androsten-17 β -yl Acetate (Norethindrone Acetate)

THOMAS STEINER

Institut für Kristallographie, Freie Universität Berlin, Takustrasse 6, D-14159 Berlin, Germany. E-mail: steiner@chemie.fu-berlin.de


(Received 4 December 1995; accepted 16 February 1996)

Abstract

The steroid skeleton of the title compound, $C_{22}H_{28}O_3$, is almost identical to the parent molecule norethindrone. The ethynyl residue donates a $C\equiv C-H\cdots O=C$ hydrogen-bond interaction, with an $H\cdots O$ separation of 2.18 \AA .

Comment

17 α -Ethynyl steroids are widely used as constituents of contraceptive agents and numerous crystal structures have been determined (*e.g.* van Geerestein, 1988). The structure of the parent molecule of the title compound, norethindrone, was reported by Moron, Lepicard & Delettre (1976). Recently, Lutz, van der Maas & Kanters (1994) pointed out that ethynyl steroids may serve as a model to study $C-H\cdots O$ interactions donated by the ethynyl residue $C\equiv C-H$. The latter is known to be one of the most acidic $C-H$ groups and therefore one of the strongest $C-H$ hydrogen-bond donors (see Desiraju, 1991; Steiner, 1994a). In this context, the crystal structure of the title compound (1) was determined.



The molecular conformation of the steroid skeleton (Fig. 1) is almost identical with that of norethindrone (Moron, Lepicard & Delettre, 1976), and therefore